Loading stock data…
Fresenius SE & Co. KGaA N (FRE.DE)
€44.69+1.39 (+3.21%)
Market ClosedLast close Sep 8
Fresenius SE & Co.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
FRE.DE in the Healthcare sector is trading at €44.69. Wall Street consensus targets €55.59 (14 analysts), implying a +24.4% move over the next 12 months. The stock is currently 16% below its 52-week high of €52.96, remaining 1.5% above its 200-day moving average. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 18) — potential for technical mean-reversion
Quarterly Financials
| Metric (EUR) | Q1 2025 | Q2 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | €5.71B↑ | €5.65B↓ | €6.16B↑ | €5.82B↓ | €5.95B |
| Gross Profit | €1.41B↓ | €1.46B↓ | €1.52B↓ | €1.53B↓ | €1.55B |
| Operating Income | €689.00M↑ | €562.00M↑ | €468.40M↓ | €601.00M↓ | €632.00M |
| Net Income | €229.00M↓ | €330.00M↓ | €361.00M↓ | €435.00M↑ | €382.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The F...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.82
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Strong income play. Yield provides a meaningful total return floor.
225.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.29%
Volume
Today's trading volume
1.66M
Recent News
All You Need to Know About Fresenius SE & Co. (FSNUY) Rating Upgrade to Buy
Fresenius SE & Co. (FSNUY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...
Fresenius SE & Co KGaA (FSNUY) delivers robust first-half results, lifting core EPS growth outlook to 10%-15% as biopharma surges 38% and Helios maintains resilient margins.
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.